NCT06376396View on ClinicalTrials.gov

Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Neurocysticercosis
Interventions
DRUG

albendazole and praziquantel

Combination of albendazole plus praziquantel

DRUG

Albendazole

Albendazole alone

All Listed Sponsors
collaborator

Muhimbili University of Health and Allied Sciences

OTHER

collaborator

National Institute for Medical Research, Tanzania

OTHER_GOV

collaborator

Sokoine University of Agriculture

OTHER

collaborator

University of Zambia

OTHER

collaborator

University Ghent

OTHER

lead

R-Evolution Worldwide S.r.l. Impresa Sociale

OTHER

NCT06376396 - Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis | Biotech Hunter | Biotech Hunter